Outcomes of Patients with Multiple Myeloma Refractory to CD38-Targeted Monoclonal Antibody Therapy

The introduction of CD38-targeting monoclonal antibodies (CD38 MoABs), daratumumab and isatuximab, has significantly impacted the management of patients with multiple myeloma (MM). Outcomes of patients with MM refractory to CD38 MoABs have not been described. We analyzed outcomes of 275 MM patients...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Leukemia
Main Authors: Gandhi, Ujjawal H, Cornell, Robert F, Lakshman, Arjun, Gahvari, Zhubin J, McGehee, Elizabeth, Jagosky, Megan H, Gupta, Ridhi, Varnado, William, Fiala, Mark A, Chhabra, Saurabh, Malek, Ehsan, Mansour, Joshua, Paul, Barry, Barnstead, Alyssa, Kodali, Saranya, Neppalli, Amarendra, Liedtke, Michaela, Narayana, Swapna, Godby, Kelly N, Kang, Yubin, Kansagra, Ankit, Umyarova, Elvira, Scott, Emma C, Hari, Parameswaran, Vij, Ravi, Usmani, Saad Z, Callander, Natalie S, Kumar, Shaji K, Costa, Luciano J
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6820050/
https://ncbi.nlm.nih.gov/pubmed/30858549
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41375-019-0435-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados